

Amendments to the claims:

This listing of claims will replace all prior versions and listings of claims pending in this application:

1. (currently amended) A method of making a dosage form ~~per se~~ containing a first medicant, which comprises
 - a) injecting through a nozzle a flowable material containing said first medicant into a mold cavity; and
 - b) hardening by cooling within the mold cavity said flowable material into a solid molded dosage form having a shape substantially the same as the mold cavity ~~into a dosage form per se, wherein substantially all of the flowable material injected into the mold cavity becomes part of the solid molded dosage form.~~
2. (original) The method of claim 1, further comprising the step of heating said flowable material prior to injecting said flowable material into said mold cavity, and wherein said hardening step (b) comprises cooling said flowable material.
3. (original) The method according to claim 2, wherein said mold cavity is heated prior to said injecting step (a) and cooled during said hardening step (b).
4. (original) The method according to claim 3, wherein said mold cavity is heated and cooled using heat transfer fluids that circulate proximal to said mold cavity.
5. (original) The method of claim 2, wherein said mold cavity is heated prior to said injection step (a) and cooled during said hardening step (b) using a single heat transfer fluid heated by a heat source and cooled by a heat sink.
6. (original) The method according to claim 1, wherein said flowable material comprises a polymer.
7. (original) The method according to claim 1, wherein said flowable material comprises a carbohydrate.

8. (original) The method according to claim 1, wherein said flowable material comprises a fat.

9. (original) The method according to claim 1, wherein said flowable material comprises a wax.

10. (original) The method according to claim 1, wherein said flowable material comprises gelatin.

11. (original) The method according to claim 10, further comprising heating said gelatin to a temperature above its gel point prior to said injecting step (a), and wherein said hardening step (b) comprises cooling said gelatin to a temperature below its gel point.

12. (original) The method of claim 1, wherein said molded dosage form is substantially free of visible defects.

13. Cancel.

14. (original) The method according to claim 1, further comprising the step of placing an insert in said mold cavity prior to said injecting step (a), such that said molded dosage form comprises an insert embedded therein.

15. (original) The method according to claim 14, wherein said insert comprises a polymer.

16. (original) The method according to claim 14, wherein said insert comprises a carbohydrate.

17. (original) The method according to claim 14, wherein said insert comprises a fat.

18. (original) The method according to claim 14, wherein said insert comprises a wax.

19. (original) The method according to claim 14, wherein said insert comprises a second medicant.
20. (original) The method according to claim 1 performed while said mold cavity is traveling along a circular path.
21. (currently amended) A method of making a molded dosage form ~~per se~~ which comprises
 - a) heating a flowable material containing a pharmaceutical active ingredient;
 - b) injecting said flowable material through an orifice into a mold cavity; and
 - c) hardening said flowable material into a solid molded dosage form ~~per se~~ having a shape substantially the same as the mold cavity; wherein said hardening step (c) comprises cooling said flowable material and wherein said mold cavity is heated prior to said injecting step (b) and cooled during said hardening step (c), wherein substantially all of the flowable material injected into the mold cavity becomes part of the solid molded dosage form.
22. (original) The method of claim 21, wherein a medicant is introduced into the mold cavity prior to said hardening step (c).

23-136 Cancel

137. (previously presented) The method of claim 1 or 14, wherein the flowable material is substantially solvent-free.